Coherus Oncology, Inc. (CHRS)
(Delayed Data from NSDQ)
$1.61 USD
+0.08 (5.23%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.61 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CHRS 1.61 +0.08(5.23%)
Will CHRS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CHRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CHRS
Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2
CHRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Other News for CHRS
CHRS forms Golden Cross on September 19
Is CHRS set to rally? Expansion Breakout shows up after rocketing 13.33%
CHRS falls 0.74% on September 17, leaving the technical picture intact
CHRS's price rises by 7.09% on September 16, though its technical setup remains stable.
MACD Bearish Signal Line Cross appears for CHRS after 1.55% move